Immunological Variables Associated to ICI Toxicity in Cancer Patients
Conditions:   Breast Cancer;   Melanoma;   Non Small Cell Lung Cancer;   Non-melanoma Skin Cancer;   Gastrointestinal Cancer;   Head and Neck Cancer;   Renal Cell Carcinoma;   Small Cell Lung Cancer;   Mesothelioma, Malignant;   Bladder Cancer;   Merkel Cell Carcinoma;   Hepatoc ellular Carcinoma;   MSI-H Colorectal Cancer Intervention:   Drug: Checkpoint Blockade, Immune Sponsor:   Jules Bordet Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 23, 2022 Category: Research Source Type: clinical trials

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
Condition:   Malignant Pleural Mesothelioma Intervention:   Drug: OT-101 Sponsor:   Oncotelic Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 21, 2022 Category: Research Source Type: clinical trials